These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 34643126

  • 1. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Islam P, Rizzieri D, Lin C, de Castro C, Diehl L, Li Z, Moore J, Morris T, Beaven A.
    Cancer Invest; 2021 Nov; 39(10):871-879. PubMed ID: 34643126
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R.
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A.
    Clin Cancer Res; 2013 Dec 15; 19(24):6882-90. PubMed ID: 24097867
    [Abstract] [Full Text] [Related]

  • 4. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
    Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A.
    Leuk Lymphoma; 2018 Dec 15; 59(12):2904-2910. PubMed ID: 29616865
    [Abstract] [Full Text] [Related]

  • 5. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE.
    Lancet Haematol; 2016 Jul 15; 3(7):e309-16. PubMed ID: 27374464
    [Abstract] [Full Text] [Related]

  • 6. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
    Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS.
    Haematologica; 2013 Apr 15; 98(4):615-9. PubMed ID: 23144193
    [Abstract] [Full Text] [Related]

  • 7. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y.
    Leuk Lymphoma; 2018 Apr 15; 59(4):863-870. PubMed ID: 28792260
    [Abstract] [Full Text] [Related]

  • 8. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
    Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, Neuberg D, Jacobsen E, Abramson JS.
    Hematol Oncol; 2018 Oct 15; 36(4):633-637. PubMed ID: 29956350
    [Abstract] [Full Text] [Related]

  • 9. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K, Bitner H, Voevoda-Dimenshtein V, Rosenberg E, Sirovsky Y, Magen H, Canaani J, Ostrovsky O, Shilo N, Shimoni A, Abraham M, Weiss L, Milyavsky M, Peled A, Nagler A.
    Biochem Pharmacol; 2019 Oct 15; 168():412-428. PubMed ID: 31325448
    [Abstract] [Full Text] [Related]

  • 10. Everolimus in diffuse large B-cell lymphomas.
    Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.
    Future Oncol; 2015 Oct 15; 11(3):373-83. PubMed ID: 25675120
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
    Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.
    Ann Oncol; 2018 Mar 01; 29(3):707-714. PubMed ID: 29253068
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
    Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodoulopoulos R, Rousseau C, Johnson N, Crump M, Morin RD, Mann KK.
    Blood; 2016 Jul 14; 128(2):185-94. PubMed ID: 27166360
    [Abstract] [Full Text] [Related]

  • 13. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K.
    Lancet Oncol; 2020 Jul 14; 21(7):978-988. PubMed ID: 32511983
    [Abstract] [Full Text] [Related]

  • 14. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS, Goh YT, SGH651 Investigators.
    Lancet Haematol; 2015 Aug 14; 2(8):e326-33. PubMed ID: 26688485
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
    Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA.
    Clin Cancer Res; 2020 Nov 01; 26(21):5579-5587. PubMed ID: 33055173
    [Abstract] [Full Text] [Related]

  • 16. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
    Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C.
    Clin Lymphoma Myeloma Leuk; 2018 Oct 01; 18(10):664-672.e2. PubMed ID: 30104176
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
    Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG.
    Lancet Oncol; 2021 Jan 01; 22(1):142-154. PubMed ID: 33301738
    [Abstract] [Full Text] [Related]

  • 18. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
    Suzuki K, Sunami K, Matsumoto M, Maki A, Shimada F, Suzuki K, Shimizu K.
    Acta Haematol; 2021 Jan 01; 144(3):264-274. PubMed ID: 33279887
    [Abstract] [Full Text] [Related]

  • 19. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M, Memmer ML, Dreyling M, Hess G.
    BMC Cancer; 2013 Jun 25; 13():308. PubMed ID: 23799873
    [Abstract] [Full Text] [Related]

  • 20. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A.
    Br J Haematol; 2017 Aug 25; 178(3):434-441. PubMed ID: 28440559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.